AU2022410770A1 - Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody - Google Patents

Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody Download PDF

Info

Publication number
AU2022410770A1
AU2022410770A1 AU2022410770A AU2022410770A AU2022410770A1 AU 2022410770 A1 AU2022410770 A1 AU 2022410770A1 AU 2022410770 A AU2022410770 A AU 2022410770A AU 2022410770 A AU2022410770 A AU 2022410770A AU 2022410770 A1 AU2022410770 A1 AU 2022410770A1
Authority
AU
Australia
Prior art keywords
fragment
antibody
protofibril
tau
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022410770A
Other languages
English (en)
Inventor
Pau ACEVES BALDO
Randall Bateman
Shobha DHADDA
Robert Gordon
Seiichi HAYATO
Michael Irizarry
Michio KANEKIYO
June Kaplow
Akihiko Koyama
Lynn Kramer
Ishani LANDRY
David Li
Eric MCDADE
Sumit RAWAL
Larisa Reyderman
Pallavi SACHDEV
Chad SWANSON
David Verbel
Kristin WILDSMITH
Jin Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Washington University in St Louis WUSTL
Original Assignee
Eisai R&D Management Co Ltd
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000937 external-priority patent/WO2023111618A1/en
Application filed by Eisai R&D Management Co Ltd, Washington University in St Louis WUSTL filed Critical Eisai R&D Management Co Ltd
Publication of AU2022410770A1 publication Critical patent/AU2022410770A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nuclear Medicine (AREA)
AU2022410770A 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody Pending AU2022410770A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163291315P 2021-12-17 2021-12-17
AUPCT/IB2021/000937 2021-12-17
US63/291,315 2021-12-17
PCT/IB2021/000937 WO2023111618A1 (en) 2021-12-17 2021-12-17 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
PCT/US2022/079509 WO2023114586A1 (en) 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Publications (1)

Publication Number Publication Date
AU2022410770A1 true AU2022410770A1 (en) 2024-06-13

Family

ID=84387973

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022410770A Pending AU2022410770A1 (en) 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Country Status (8)

Country Link
US (1) US20250051427A1 (https=)
EP (1) EP4448005A1 (https=)
JP (1) JP2024547001A (https=)
KR (1) KR20240115910A (https=)
AU (1) AU2022410770A1 (https=)
CA (1) CA3242280A1 (https=)
MX (1) MX2024007288A (https=)
WO (1) WO2023114586A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025019457A1 (en) 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025049938A1 (en) * 2023-08-31 2025-03-06 Florida Atlantic University Board Of Trustees Non-invasive delivery method of antibodies to the brain for treatment of brain diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210324056A1 (en) * 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN112187401B (zh) 2019-07-03 2022-06-14 华为技术有限公司 多时间单元传输方法及相关装置
US11877315B2 (en) 2020-09-15 2024-01-16 Qualcomm Incorporated Wireless device digital beamforming capability indication

Also Published As

Publication number Publication date
KR20240115910A (ko) 2024-07-26
EP4448005A1 (en) 2024-10-23
WO2023114586A1 (en) 2023-06-22
MX2024007288A (es) 2024-06-28
CA3242280A1 (en) 2023-06-22
JP2024547001A (ja) 2024-12-26
US20250051427A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
US20220372123A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
WO2023111618A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
TW202334201A (zh) 抗Ｔａｕ抗體之組成物、劑型及方法
KR20250107906A (ko) 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
US20240352109A1 (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
TW202313111A (zh) 治療阿茲海默症之方法
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法
US20250361292A1 (en) Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
WO2025240435A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
WO2025147562A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
CN118215497A (zh) 抗tau抗体组合物、剂型和方法
WO2026025002A1 (en) Methods of treating neurological disorders with anti-abeta antibodies